Humacyte (NASDAQ:HUMA) Upgraded at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA – Free Report) from a sell rating to a hold rating in a research report report published on Friday.

A number of other brokerages have also recently commented on HUMA. D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Monday, June 9th. HC Wainwright assumed coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a “buy” rating and a $4.00 price target on the stock. Finally, Benchmark reduced their price target on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Humacyte has an average rating of “Moderate Buy” and a consensus target price of $11.71.

Read Our Latest Report on Humacyte

Humacyte Trading Down 4.5%

Shares of HUMA opened at $2.12 on Friday. The firm’s 50 day simple moving average is $2.06 and its 200 day simple moving average is $2.99. The company has a market capitalization of $328.85 million, a P/E ratio of -3.07 and a beta of 1.99. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.68 and a quick ratio of 3.28. Humacyte has a 1-year low of $1.15 and a 1-year high of $9.79.

Humacyte (NASDAQ:HUMA – Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.46 million. Sell-side analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Dale A. Sander acquired 20,000 shares of the stock in a transaction on Thursday, April 10th. The stock was acquired at an average price of $1.53 per share, with a total value of $30,600.00. Following the completion of the transaction, the chief financial officer now owns 40,600 shares of the company’s stock, valued at $62,118. This represents a 97.09% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of Humacyte stock in a transaction that occurred on Tuesday, April 8th. The stock was acquired at an average price of $1.32 per share, with a total value of $66,000.00. Following the completion of the acquisition, the director now directly owns 91,207 shares in the company, valued at $120,393.24. This represents a 121.34% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 83,993 shares of company stock valued at $118,224 over the last quarter. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humacyte

Large investors have recently bought and sold shares of the business. Integrity Alliance LLC. bought a new stake in shares of Humacyte during the 1st quarter valued at about $112,000. Woodline Partners LP grew its stake in shares of Humacyte by 38.7% during the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock valued at $6,735,000 after purchasing an additional 1,101,198 shares during the period. Polar Asset Management Partners Inc. bought a new stake in shares of Humacyte during the 1st quarter valued at about $852,000. RA Capital Management L.P. bought a new stake in shares of Humacyte during the 1st quarter valued at about $5,648,000. Finally, Kodai Capital Management LP bought a new stake in shares of Humacyte during the 1st quarter valued at about $124,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

(Get Free Report)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

Further Reading